Patients with chronic renal failure (CRF) may exhibit various cutaneous abnormalities, including changes in skin colour, pruritus, xerosis, hair, nail and oral changes, metastatic calcinosis, and bullous dermatosis. These changes have a considerable negative effect on the patient's quality of life. Early recognition of cutaneous signs and prompt initiation of treatment can dramatically alter their course and decrease morbidity.
GrassiSCioccaOBrazzelliV. Cute e rene: Rischio ed entità dell'interessamento renale nelle malattie dermatologiche. Boll Soc Med Chir Pavia2011; 124:755–62.
2.
CordovaKBObergTJMalikMRobinson-BostomL. Dermatologic conditions seen in end-stage renal disease. Semin Dial2009; 22:45–55.
3.
OnelmisHSenerSSasmazS. Cutaneous changes in patients with chronic renal failure on hemodialysis. Cutan Ocul Toxicol2012; 1–6.
4.
Robinson-BostomLDiGiovannaJJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol2000; 43:975–86.
PisoniRLWilkströmBElderSJ. Pruritus in haemodialysis patients: International results from the Dialysis Outcome and Practice Patterns Study (DOPPS). Nephrol Dial Transplant2006; 21:3495–505.
7.
Abdelbaqi-SalhabMShalhubSMorganMB. A current review of the cutaneous manifestations of renal disease. J Cutan Pathol2003; 30:527–38.
UdayakumarPBalasubramanianSRamalingamKS. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermatol Venereol Leprol2006; 72:119–25.
10.
LöcseyLLenkeyÀLeöveyA. Hormonal changes in haemodialysed and in kidney- transplantes patients. Int Urol Nephrol1987; 19:201–13.
11.
AvermaeteAAltmeyerPBacharach-BuhlesM. Skin changes in dialysis patients: A review. Nephrol Dial Transplant2001; 16:2293–6.
LupiORezendeLZangrandoM. Cutaneous manifestations in end-stage renal disease. An Bras Dermatol2011; 86:319–26.
15.
WeigleJPBroomeDR. Nephrogenic systemic fibrosis: Chronic imaging findings and review of the medical literature. Skeletal Radiol2008; 37:457–64.
16.
EliasJJrSantosACKoenigkam-SantosMNogueira-BarbosaMHMugliaVF. Complicações do uso intravenoso de agentes de contraste à base de gadolínio para ressonância magnética. Radiol Bras2008; 41:263–7.
17.
ChiricozziAZhangSDattolaAGabelliniMChimentiSNisticòSP. Role of Th17 in the pathogenesis of cutaneous inflammatory diseasesJ Biol Regul Homeost Agents2012; 26(3):313–8.
18.
ChiricozziAZhangSDattolaACannizzaroMVGabelliniMChimentiSNisticòS. New insights in the pathogenesis of cutaneous autoimmune disorders. J Biol Regul Homeost Agents2012; 26(2): 165–70.
19.
SaracenoRNisticòSPCapriottiEChimentiS. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: A controlled study. Dermatol Ther2009; 22:391–94.
20.
SaracenoRNisticòSPCapriottiEde FeliceCRhodesLEChimentiS. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed2009; 24:43–45.
21.
NisticòSChiricozziASaracenoRSchipaniCChimentiS. Vitiligo treatment with monochromatic excimer light and tacrolimus: Results of an open randomized controlled study. Photomed Laser Surg2012; 30:26–30.
22.
NisticòSPSaracenoRChiricozziAGiuntaADi StefaniAZerbinatiN. UVA-1 Laser in the treatment of palmoplantar pustular psoriasis. Photomed Laser Surg2013; 31:434–38.
